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of anti-TB drug resistance both from smear-positive sputum
samples and cultures. Recently, we developed RBHAs for
detection of mutations at the gyrA gene and at the rrs and
rpsL genes, which are responsible for XDR-TB.
Lastly, we developed an RBHA-based dual test for TB/NTM
identiﬁcation and detection of mutations at the rpoB gene,
which are the most critical information of MDR-TB using one
set of primers. This was possible because the polymorphic
regions for Mycobacterium species identiﬁcation and for
mutations involved in resistance to RIF are located closed
within 360 bp.
Throughout our exercises in evaluating these molecular
diagnostic tests, we found advantages and problems
in implementing them to the clinical mycobacteriology
laboratories, and these points will be discussed with
numerous examples.
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Background: Tuberculosis (TB) remains one of the major
public health problems worldwide, with 95% of cases and
98% of deaths occurring in developing countries. According
to the epidemiological surveillance carried out in 2000,
approximately 550 million individuals in China have been
infected with Mtb. based on the result of TST. Nevertheless,
TST has been shown inferior to Interferon-Gamma Release
Assay (IGRA) in terms of the speciﬁcity and sensitivity as
reported in countries with low incidence of tuberculosis.
Therefore, both the diagnostic value of IGRA in the setting
of china and the number of Mtb. infection determined by
IGRA warrant investigation.
Objectives: (1) To evaluate the sensitivity and speciﬁcity
of an in-house Mtb. speciﬁc IFN-g Elispot kit in diagnosis
of Mtb. infection. (2) To investigate the prevalence of Mtb.
infection in different population using the in-house Elispot
kit.
Methods: By screening the IFN-g response to different
antigen proteins (eg. recombinant ESAT-6 protein) and
individual peptides derived from Mtb. antigens, an in-
house IFN-g Elispot kit was developed. The sensitivity
and speciﬁcity of the in-house Elispot kit in diagnosis of
tuberculosis were evaluated in paralleled comparison with
commercial Quantiferon-TB-Gold. The prevalence of Mtb.
infection in different healthy populations in Shenzhen was
investigated using the in-house Elispot kit and compared
with TST.
Results: The sensitivity and speciﬁcity of in-house Elispot kit
for diagnosis of tuberculosis were 86% and 92%, respectively,
both of which are comparable with the commercial
Quantiferon-TB-Gold and signiﬁcantly higher than TST. In
addition, the price of in-house Elispot kit was only about
1/4 of commercial kits such as Qunatiferon-TB-Gold or
T.SPOT.TB. Using the Elispot assay, the prevalence of Mtb.
infection in healthy population varied from 5.88% to 55.6%
depends on their exposure to active tuberculosis cases.
Conclusion: An in-house affordable IGRA kit for diagnosis
of Mtb. infection has been developed with sensitivity
and speciﬁcity comparable to that of commercial kits.
The prevalence of Mtb. infection in healthy population
determined by IGRA is signiﬁcantly lower than that of TST.
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Insulin resistance (IR) is more often seen in chronic hepatitis
virus C infection than in other forms of chronic liver
disease. Recent research indicates that IR seen in patients
chronically infected with HCV may be directly caused or
at least favoured by the virus itself. In the transgenic
mice model the HCV core protein has been shown to
induce IR as a consequence of increased TNF production.
Other mechanisms have been also proposed, based on the
activation of a number of cytokines, and on generation
of oxidative stress, as consequence of the direct effect
of the HCV and of HCV proteins on mitochondria and
on the hepatocyte endoplasmic reticulum. Recent results
obtained in our laboratory implicate endogenous interferon
production in HCV related IR due to common intracellular
signalling shared by interferon and insulin.
IR has a number of clinical consequences in hepatitis C.
It associates with more rapid progression of ﬁbrosis and
with reduced response to antiviral therapy with interferon
or peghilated-interferon and ribavirin. The mechanisms
by which IR promotes ﬁbrosis progression in the liver
of patients with HCV include: development of hepatic
steatosis, hyperleptinemia, increased TNF production and
reduce expression of PPARg receptors. These concepts have
practical implications for the management of patients with
HCV, and diet and exercise aimed to reduce metabolic
abnormalities should be recommended, particularly in
overweighted cases.
Several studies have clearly demonstrated that sustained
virological response to interferon-based therapy is
signiﬁcantly reduced in patients with HCV and high
Homeostasis Model of Assessment (HOMA) IR index. This
effect is independent of presence of type 2 diabetes and
of obesity and is already evident with HOMA values >3.
We have recently shown that baseline hyperinsulinemia has
inhibitory effects on serum HCV-RNA decay seen as early as
24 hours after the ﬁrst injection of pegylated-interferon,
indicating direct downregulation by insulin of intracellular
IFN signalling. The impairment of the early antiviral
response correlate with reduces sustained response to PEG-
IFN plus ribavirin treatment. Several studies have now
conﬁrmed reduced SVR in patients with IR, independently
of the HCV genotype. Interestingly patients with SVR
experienced a signiﬁcant reduction in the HOMA index
that returned within the normal range at the time of HCV
clearance, suggesting a direct relationship between HCV
replication and IR.
Obviously IR seen in patients with HCV is not always related
to direct effects of HCV and may also occur as consequence
of the classical metabolic syndrome frequently seen in the
general population, particularly in the Western civilized
countries. However, also in these cases IR is associated
with more progressive liver disease and reduces response to
antiviral therapy and should be therefore corrected when
possible.
Ongoing studies are assessing the role of insulin sensitisers
(metformine, pioglitazone) for improving the response to
antiviral therapy in HCV patients with IR, but results so far
reported have been controversial and inconclusive.
